Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 49 |
| Active Pipeline (Recruiting Now) | 29 (10) |
| Completed vs Stopped Early | 1 / 19 (38.8%) |
| Median Closed Actual Enrollment | 118 participants |
| Physical Hospital Site Disclosure | 88.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Clinica Universidad de Navarra | Pamplona, Navarre | 10 |
| Hospital Universitario 12 de Octubre | Madrid | 9 |
| MD Anderson Cancer Center | Houston, TX | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant O | Phase III | RECRUITING |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers | Phase II | RECRUITING |
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participan | Phase III | RECRUITING |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer | Phase II | RECRUITING |
| NCT05578976 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphami | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Genmab Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.